|Mr. Dietrich John Pauls M.B.A., MBA||Pres, CEO & Director||612.65k||N/A||1971|
|Mr. Scott B. Kellen C.A.||CFO & Company Sec.||341.25k||N/A||1965|
|Dr. Harry W. Alcorn Jr.||Chief Medical Officer||356.55k||N/A||1956|
|Dr. Edward G. Calamai||Consulting Head of Manufacturing||N/A||N/A||N/A|
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.
DiaMedica Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.